NCT02881242View on ClinicalTrials.gov

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2025

Conditions
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Trametinib

Given PO

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Novartis

INDUSTRY

collaborator

Prostate Cancer Foundation

OTHER

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT02881242 - Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter